The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Market Value Is Anticipated For The Locally Advanced Pancreatic Cancer Market Over The Period 2026–2030?
The market size for locally advanced pancreatic cancer has seen rapid expansion in recent years. Projections indicate it will expand from $1.05 billion in 2025 to $1.16 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 10.5%. Historically, this growth can be ascribed to factors such as the late-stage diagnosis of pancreatic cancer, restricted surgical eligibility for locally advanced cases, a longstanding dependence on gemcitabine-based chemotherapy, low overall survival rates, and the expansion of hospital-based oncology care.
The market size for locally advanced pancreatic cancer is set to experience swift expansion over the coming years, with projections indicating it will reach $1.71 billion by 2030, achieving a compound annual growth rate (CAGR) of 10.2%. This anticipated growth can be credited to the wider implementation of combination therapy protocols, the increasing uptake of SBRT, a surge in investment dedicated to pancreatic cancer research, a heightened focus on personalized oncology care, and the growing accessibility of advanced treatment centers. Significant trends observed during this forecast period include the escalating use of combination chemotherapy regimens, the rising adoption of neoadjuvant treatment approaches, an increased emphasis on tumor downstaging to enhance surgical eligibility, the broadening application of radiation therapy for managing local disease, and a strengthening focus on multidisciplinary strategies for treatment planning.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21214&type=smp
What Drivers Are Expected To Influence The Locally Advanced Pancreatic Cancer Market During The Forecast Period?
The rising incidence of tobacco consumption is anticipated to propel the growth of the locally advanced pancreatic cancer markets in the foreseeable future. Tobacco, a plant cultivated for its leaves used in products like cigarettes and cigars, contains nicotine, an addictive compound associated with severe health problems including cancer and heart disease. The uptick in tobacco use is influenced by elements such as ready availability, affordability, targeted marketing, societal acceptance in specific areas, and smoking prompted by stress. This consumption represents a significant risk factor for the onset of locally advanced pancreatic cancer, contributing to a higher prevalence of pancreatic malignancies. Illustratively, in October 2024, a study on youth smoking trends by the European Respiratory Society’s (ERS), a Switzerland-based non-profit organization, indicated a notable increase in smoking rates, with 22.5% of respondents smoking in 2022 escalating to 40.1% in 2024. Hence, the observed growth in tobacco consumption is a key driver for the expansion of the locally advanced pancreatic cancer market.
How Is The Locally Advanced Pancreatic Cancer Market Divided Into Its Major Segments?
The locally advanced pancreatic cancer market covered in this report is segmented –
1) By Therapy: Chemotherapy, Radiation Therapy
2) By Route Of Administration: Oral, Injectables, Other Routes Of Administrations
3) By End-User: Hospital, Specialty Clinics, Research Institutions, Other End-Users
Subsegments:
1) By Chemotherapy: Gemcitabine-based Chemotherapy, FOLFIRINOX Chemotherapy
2) By Radiation Therapy: External Beam Radiation Therapy, Stereotactic Body Radiation Therapy (SBRT)
Which Trends Are Influencing The Locally Advanced Pancreatic Cancer Market?
Companies operating within the locally advanced pancreatic cancer market are prioritizing the development of innovative products, including orphan drugs, to enhance available treatment options, improve patient outcomes, and address significant unmet medical needs associated with this aggressive disease. Orphan drugs are specifically developed for rare conditions impacting a small number of individuals, receiving encouragement from regulatory authorities through benefits like tax reductions and market exclusivity to stimulate their development. For example, in January 2025, Actuate Therapeutics Inc., a US-based biopharmaceutical company, announced that its compound, Elraglusib, a new GSK-3β inhibitor, was granted Orphan Drug Designation by both the European Medicines Agency (EMA) and US Food and Drug Administration (FDA) for the treatment of pancreatic ductal adenocarcinoma (PDAC) (a potential types of locally advanced pancreatic cancer). This designation underscores its potential to bridge a critical gap in treating this severe cancer, especially given promising Phase 2 trial results that showed substantial clinical improvements and anti-tumor effects in metastatic PDAC patients.
Who Are The Prominent Organizations Shaping The Locally Advanced Pancreatic Cancer Market?
Major companies operating in the locally advanced pancreatic cancer market are Pfizer Inc, F Hoffmann La Roche Ltd, Merck and Co Inc, Bristol Myers Squibb Company, AstraZeneca plc, AbbVie Inc, Novartis AG, GSK plc, Bayer AG, Eli Lilly and Company, Ipsen, Takeda Pharmaceutical Company Limited, Amgen Inc, Sanofi, Servier, NovoCure Limited, Halozyme Therapeutics, Clovis Oncology, Astellas Pharma, BeiGene
Read the full locally advanced pancreatic cancer market report here:
Which Region Is Forecast To Lead The Locally Advanced Pancreatic Cancer Market In Terms Of Market Size?
North America was the largest region in the locally advanced pancreatic cancer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the locally advanced pancreatic cancer market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Locally Advanced Pancreatic Cancer Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=21214&type=smp
Browse Through More Reports Similar to the Global Locally Advanced Pancreatic Cancer Market 2026, By The Business Research Company
Invasive Ductal Carcinoma Therapeutics Global Market Report
Pancreatic Cancer Drugs Global Market Report
https://www.thebusinessresearchcompany.com/report/pancreatic-cancer-drugs-global-market-report
Gastroesophageal Junction Adenocarcinoma Therapeutics Global Market Report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model